- Home
- LBTYB vs APLS Comparison
LBTYB vs APLS Comparison
Compare LBTYB & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBTYB
- APLS
- Stock Information
- Founded
- LBTYB 2004
- APLS 2009
- Country
- LBTYB Bermuda
- APLS United States
- Employees
- LBTYB N/A
- APLS N/A
- Industry
- LBTYB Cable & Other Pay Television Services
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- LBTYB Telecommunications
- APLS Health Care
- Exchange
- LBTYB Nasdaq
- APLS Nasdaq
- Market Cap
- LBTYB 4.0B
- APLS 3.6B
- IPO Year
- LBTYB N/A
- APLS 2017
- Fundamental
- Price
- LBTYB $11.11
- APLS $27.52
- Analyst Decision
- LBTYB
- APLS Buy
- Analyst Count
- LBTYB 0
- APLS 18
- Target Price
- LBTYB N/A
- APLS $46.71
- AVG Volume (30 Days)
- LBTYB 195.0
- APLS 1.4M
- Earning Date
- LBTYB 01-01-0001
- APLS 02-28-2025
- Dividend Yield
- LBTYB N/A
- APLS N/A
- EPS Growth
- LBTYB N/A
- APLS N/A
- EPS
- LBTYB 4.23
- APLS N/A
- Revenue
- LBTYB $4,341,900,000.00
- APLS $715,216,000.00
- Revenue This Year
- LBTYB $2.22
- APLS $97.25
- Revenue Next Year
- LBTYB N/A
- APLS $12.68
- P/E Ratio
- LBTYB $2.54
- APLS N/A
- Revenue Growth
- LBTYB 3.53
- APLS 162.10
- 52 Week Low
- LBTYB $11.02
- APLS $24.34
- 52 Week High
- LBTYB $21.90
- APLS $71.90
- Technical
- Relative Strength Index (RSI)
- LBTYB 26.20
- APLS 38.99
- Support Level
- LBTYB $11.80
- APLS $26.84
- Resistance Level
- LBTYB $11.40
- APLS $28.59
- Average True Range (ATR)
- LBTYB 0.02
- APLS 1.12
- MACD
- LBTYB 0.03
- APLS -0.03
- Stochastic Oscillator
- LBTYB 12.33
- APLS 18.09
About LBTYB Liberty Global Ltd. Class B
Liberty Global is a holding company with interests in several telecom companies in the UK, Netherlands, Belgium, Switzerland, Ireland, and Slovakia. Liberty is the owner of the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile-network-operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.